Published in Oncogene on September 30, 2004
Role of survivin and its splice variants in tumorigenesis. Br J Cancer (2005) 1.66
Survivin study: an update of "what is the next wave"? J Cell Physiol (2006) 1.63
Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med (2013) 1.40
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer (2005) 1.26
Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. J Exp Clin Cancer Res (2006) 1.09
Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J Biol Chem (2007) 1.01
Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells. Invest New Drugs (2013) 0.85
Clinico-pathologic relevance of Survivin splice variant expression in cancer. Cancer Lett (2013) 0.84
Survivin-2B promotes autophagy by accumulating IKK alpha in the nucleus of selenite-treated NB4 cells. Cell Death Dis (2014) 0.82
Hydroxycamptothecin induces apoptosis and inhibits tumor growth in colon cancer by the downregulation of survivin and XIAP expression. World J Surg Oncol (2013) 0.82
Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation. Onco Targets Ther (2012) 0.80
Suppressed diversity of survivin splicing in active rheumatoid arthritis. Arthritis Res Ther (2015) 0.79
Bifunctional roles of survivin-ΔEx3 and survivin-2B for susceptibility to apoptosis in endometrial carcinomas. J Cancer Res Clin Oncol (2014) 0.79
microRNA-mediated survivin control of pluripotency. J Cell Physiol (2015) 0.78
A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines. Invest New Drugs (2005) 0.75
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget (2011) 2.28
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem (2006) 1.83
Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem (2004) 1.73
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res (2010) 1.64
Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell (2009) 1.60
Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer (2008) 1.52
Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res (2007) 1.42
Contribution of Vh gene replacement to the primary B cell repertoire. Immunity (2003) 1.32
KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem (2006) 1.30
PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res (2003) 1.29
Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis (2007) 1.29
Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem (2005) 1.27
VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. Mol Cancer Res (2006) 1.26
DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther (2002) 1.26
Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques (2004) 1.21
Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat (2006) 1.20
Induction of cell cycle arrest by human T-cell lymphotropic virus type 1 Tax in hematopoietic progenitor (CD34+) cells: modulation of p21cip1/waf1 and p27kip1 expression. J Virol (2005) 1.13
Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther (2004) 1.12
Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer (2005) 1.10
Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res (2010) 1.10
Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol (2012) 1.08
Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation. Blood (2009) 1.08
Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res (2010) 1.07
Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. Prostate (2011) 1.06
A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS One (2012) 1.05
The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncol (2009) 1.04
The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Mol Cancer Ther (2006) 1.04
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer (2009) 1.03
Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. Cell Cycle (2011) 1.02
Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J Biol Chem (2007) 1.01
Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively. J Biol Chem (2004) 1.00
Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene (2003) 0.99
MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia. Mol Cell Biol (2011) 0.98
Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther (2008) 0.97
Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology (2004) 0.96
Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther (2007) 0.96
Effects of human papillomavirus type 16 oncoproteins on survivin gene expression. J Gen Virol (2006) 0.96
Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53. Biochem Biophys Res Commun (2005) 0.93
Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer (2006) 0.91
Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Exp Hematol (2007) 0.91
Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr Dev Pathol (2005) 0.91
Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther (2012) 0.91
Molecular mechanism of upregulation of survivin transcription by the AT-rich DNA-binding ligand, Hoechst33342: evidence for survivin involvement in drug resistance. Nucleic Acids Res (2007) 0.90
Antitumor activity of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration. Mol Pharm (2014) 0.89
Methylation of RASSF1A gene promoter is regulated by p53 and DAXX. FASEB J (2012) 0.88
An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). Am J Transl Res (2013) 0.87
Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin. Am J Transl Res (2009) 0.87
Transmembrane TNF-alpha mediates "forward" and "reverse" signaling, inducing cell death or survival via the NF-kappaB pathway in Raji Burkitt lymphoma cells. J Leukoc Biol (2008) 0.86
Molecular mechanism of serial VH gene replacement. Ann N Y Acad Sci (2003) 0.85
Expression and functional role of inhibitor-of-apoptosis protein livin (BIRC7) in neuroblastoma. Biochem Biophys Res Commun (2010) 0.84
Glycogen synthase kinase 3beta induces apoptosis in cancer cells through increase of survivin nuclear localization. Cancer Lett (2008) 0.84
Expression of TNF-alpha leader sequence renders MCF-7 tumor cells resistant to the cytotoxicity of soluble TNF-alpha. Breast Cancer Res Treat (2008) 0.83
High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity. Oncol Rep (2009) 0.83
Translation of TRAF1 is regulated by IRES-dependent mechanism and stimulated by vincristine. Nucleic Acids Res (2010) 0.82
Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo. Cancer Immunol Immunother (2006) 0.82
Structural insights into Paf1 complex assembly and histone binding. Nucleic Acids Res (2013) 0.82
High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy. Prostate (2013) 0.82
A noncoding RNA regulates human protease-activated receptor-1 gene during embryogenesis. Biochim Biophys Acta (2002) 0.82
Hypertensive epidemiology in Heilongjiang Province in China. Chin Med J (Engl) (2002) 0.81
Berberine represses DAXX gene transcription and induces cancer cell apoptosis. Lab Invest (2013) 0.81
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol (2010) 0.81
V(D)J recombinatorial repertoire diversification during intraclonal pro-B to B-cell differentiation. Blood (2002) 0.81
A switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicity. PLoS Comput Biol (2011) 0.80
Loss of inhibitor of apoptosis proteins as a determinant of polyamine analog-induced apoptosis in human melanoma cells. Oncogene (2003) 0.80
Inhibition of nuclear factor-kappaB activation is essential for membrane-associated TNF-alpha-induced apoptosis in HL-60 cells. Immunol Cell Biol (2006) 0.80
Tissue factor/FVIIa activates Bcl-2 and prevents doxorubicin-induced apoptosis in neuroblastoma cells. BMC Cancer (2008) 0.80
MycN is a transcriptional regulator of livin in neuroblastoma. Oncol Rep (2009) 0.78
Comparison of DR5 and Fas expression levels relative to the chemosensitivity of acute lymphoblastic leukemia cell lines. Leuk Res (2002) 0.78
Down-regulation of tissue factor by siRNA increased doxorubicin-induced apoptosis in human neuroblastoma. J Huazhong Univ Sci Technolog Med Sci (2008) 0.76
161: COMBINATION OF BNP WITH LVDD FOR PREDICTION OF MORTALITY IN PATIENTS WITH SEPTIC SHOCK. Crit Care Med (2016) 0.75
Study on the expression of IkappaB-alpha protein in TNF-alpha induced apoptosis of U937 cells. Zhonghua Xue Ye Xue Za Zhi (2002) 0.75